Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of the various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected firstly in intestine, which are often known as carcinoid tumors, pancreas is the second most prime organ in the body where the growth of NET is common.
Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/129
The neuroendocrine tumor treatment market is expected to gain steady traction in the foreseeable future as there are many products in various pharmaceutical company product pipeline. As there is an increase in NET incidence in various geographies, there is a need for fast tract drug approval process which will bring the products in market in a very short time.
The growing incidence of GI and Lung Neuroendocrine Tumors is a key factor fueling growth of the global neuroendocrine tumor treatment market. According to a research study published by Novartis in 2015, GI Neuroendocrine comprises 61% Neuroendocrine Tumors (NET) diagnosis and 5%-44% of GI NET have advanced disease at time of diagnosis, with survival rate drastically decreasing according to severity. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors which influence the NET are hormonal imbalance at pituitary gland and thyroid gland. Rising demand for various imagining technique in North America and Europe are factors projected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit the excess hormone production, are some of the other factors augmenting growth of the global neuroendocrine tumor treatment market.
Innovate drug in pharmaceutical company product pipeline to boost the Neuroendocrine Tumor Treatment Market
There are various medical treatment to treat cancer, and targeted therapy is one of the most preferred to treat neuroendocrine tumor treatment. Targeted therapy is a futuristic and highly effective approach for treating cancers and hence, targeted NET therapies are projected to gain significant demand in the near future. Though somatostatins are effective in treating some types of pituitary tumors, regulatory approval for NET is expected to further encourage its research as a combination therapy with targeted drugs. Pasireotide is another somatostatin analogue under study for treating NET. Somatostain analogs are the preferred therapy for chronic control and are effective for long-term management.
Imaging technique is one of the useful tools for assessing key tumor which in turn will boost growth of the neuroendocrine tumor treatment market
There are various other types of neuroendocrine tumors that may occur across various parts of the body and have different growth patterns. The other neuroendocrine tumors include thymus, thyroid gland, adrenal gland and pituitary gland. These neuroendocrine cells multiply at a very slow pace as compared to a regular neuroendocrine cells of GI, Lungs, and Pancreases. These seldom cause symptoms at an early diseases stage, however, when these symptoms are identified they are sometimes misdiagnosed as any other lump. It is highly important to identify the other neuroendocrine tumors, as if left undiagnosed, condition may lead to malignant tumor. Proper treatment planning is necessary as Neuroendocrine Tumor Treatment that can otherwise be contained in a particular area of the body, may spread to nearby tissues or lymph nodes and may eventually spread throughout the body. There are limited treatment options for pancreatic neuroendocrine tumors. One of the most significant and common treatment is surgical removal of tumors. Apart from surgical treatment, there are few treatments such as chemotherapy, targeted therapy, radiation therapy, etc.
Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/129